Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
CA 2796440 C · Owner: Academisch Ziekenhuis Leiden · Inventors: Van Ommen, Garrit-Jan Boudewijn; Van Deutekom, Judith Christina Theodora; Aartsma-Rus, Annemieke
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides a method for generating an oligonucleotide with which an exon may be skipped in a pre-mRNA and thus excluded from a produced mRNA thereof. Further provided are methods for altering the secondary structure of an mRNA to interfere with splicing processes and uses of the oligonucleotides and methods in the treatment of disease. Further provided are pharmaceutical compositions and methods and means for inducing skipping of several exons in a pre-mRNA.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 21, 2003 and granted August 27, 2019. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 21, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 21, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.